Methods: We contacted all authors who published case reports describing incomplete resection of Frantz’s tumor between 1985 and 2008 to request follow-up information.
Results: Follow-up information was obtained for 11 out 18 patients
who underwent Epigenetic inhibitor incomplete resection.
Estimated median survival rate was 5.7 years (69.5 months).
Conclusion: Since Frantz’s tumor typically develops mainly in children and young women, a 5.7 year survival rate is unacceptable. Thus complete resection of locally invasive solid-pseudopapillary tumor of the pancreas is always justified, even at the price of difficult, mutilating surgery. (C) 2009 Elsevier Ltd. All rights reserved.”
“High quality multiple quantum well Al0.35Ga0.65N active layers with narrow wells designed for ultraviolet (UV) light-emitting diodes using the phonon engineering approach are characterized using quasi-steady-state and time-resolved photoluminescence spectroscopy. The photoluminescence intensity decrease with temperature increasing from 10 to 300 K was very small, and the upper limit of the internal quantum efficiency (IQE) of up to 70% was estimated based on this temperature dependence. Carrier lifetime measurements yielded the lower bound
of the IQE to be similar to 35% under optical pumping, whereas IQE of similar to 25% was estimated from the measured external quantum efficiency and the light extraction efficiency calculated by ray tracing. The observed photoluminescence features and the high IQE are interpreted as a consequence of strong carrier (exciton) localization. (C) 2009 American Institute of Physics. [DOI: 10.1063/1.3103321]“
“Background: Glucocorticoids MS-275 cell line (GC) are the mainstay of treatment of polymyalgia rheumatica (PMR). However GC-related adverse events occur frequently, particularly in patients with relapsing disease. Several studies have demonstrated that IL-6 is a key player in the pathogenesis of PMR.
Objectives: To report 2 patients with PMR treated with the anti-IL-6 check details receptor monoclonal antibody tocilizumab (TCZ) and to review the published evidence on the efficacy and safety of TCZ in patients with PMR.
Methods: We
treated 2 GC-naive patients with newly diagnosed pure PMR with monthly TCZ infusions (8 mg/kg body weight) for 6 months. Disease activity and drug tolerability were assessed clinically, by laboratory tests, and bilateral shoulder ultrasonography before starting the treatment and subsequently every month during TCZ therapy. We performed a systematic literature search (PubMed until July 2012) using the terms “”tocilizumab,”" “”anti-IL-6-receptor,”" “”polymyalgia rheumatica,”" “”giant cell arteritis”", and “”large-vessel vasculitis”" to identify published reports of patients with PMR treated with TCZ.
Results: One of our patients responded well to TCZ, while the other patient required GC therapy after the 2nd TCZ infusion because of lack of appreciable clinical response.